Valuation: AstraZeneca PLC

Market Cap 244B 218B 203B 184B 347B 23,606B 350B 2,438B 953B 11,995B 915B 895B 38,578B P/E 2026 *
20.3x
P/E 2027 * 17.4x
Enterprise Value 263B 235B 219B 199B 375B 25,510B 379B 2,634B 1,030B 12,963B 989B 967B 41,689B EV / Sales 2026 *
4.17x
EV / Sales 2027 * 3.81x
Free-Float
96.62%
Yield 2026 *
2.13%
Yield 2027 * 2.26%
1 day-2.36%
1 week-1.16%
Current month-3.16%
1 month+0.13%
3 months-16.49%
6 months-21.85%
Current year-13.76%
1 week 11,716
Extreme 11716
12,180
1 month 11,552
Extreme 11552
12,788
Current year 10,524
Extreme 10524
15,732
1 year 10,524
Extreme 10524
15,732
3 years 9,461
Extreme 9461
15,732
5 years 8,090.32
Extreme 8090.32
15,732
10 years 3,996
Extreme 3996
15,732
Manager TitleAgeSince
Chief Executive Officer 66 01/10/2012
Director of Finance/CFO 52 01/08/2021
Chief Operating Officer 55 01/06/2015
Director TitleAgeSince
Director/Board Member 70 06/04/1999
Director/Board Member 66 01/10/2012
Director/Board Member 65 27/04/2017
Date Insider Type Main position Quantity % Market Cap. Importance
9/14/26 A Free

Chief Financial Officer

73 0.0000%
9/14/26 A Buy

Chairman

2,500 0.0002%
9/14/26 A Buy

Chief Executive Officer

60,000 0.0039%
Change 5-day change 1-year change 3-year change Capi.($)
-2.36%-1.16%-7.14%+8.68% 249B
-1.61%+1.72%+38.30%+106.93% 1,060B
-0.76%-0.84%+35.21%+62.70% 623B
+0.39%+4.81%+17.81%+83.77% 480B
-0.29%-0.99%+64.79%+37.06% 352B
-2.03%+1.06%+21.08%+42.16% 345B
-1.92%-0.29%+10.54%+33.20% 274B
-1.37%+0.04%+38.29%+52.33% 223B
+0.17%-0.27%+24.40%+96.82% 182B
-1.58%-0.04%-34.99%-61.27% 168B
Average -1.12%+0.45%+20.83%+46.24% 395.61B
Weighted average by Cap. -1.07%+0.72%+27.64%+63.29%

Financials

2026 *2027 *
Net sales 63.16B 56.4B 52.61B 47.79B 89.94B 6,117B 90.81B 632B 247B 3,108B 237B 232B 9,996B 67.04B 59.87B 55.85B 50.74B 95.47B 6,493B 96.4B 671B 262B 3,300B 252B 246B 10,611B
Net income 11.9B 10.62B 9.91B 9B 16.94B 1,152B 17.11B 119B 46.54B 586B 44.67B 43.7B 1,883B 13.84B 12.36B 11.53B 10.47B 19.71B 1,340B 19.9B 138B 54.13B 681B 51.95B 50.83B 2,190B
Net Debt 19.66B 17.56B 16.38B 14.88B 27.99B 1,904B 28.27B 197B 76.91B 968B 73.81B 72.21B 3,112B 11.99B 10.7B 9.98B 9.07B 17.07B 1,161B 17.23B 120B 46.89B 590B 45B 44.02B 1,897B
Projected Income Statement - Annual - AstraZeneca PLC
Logo AstraZeneca PLC
AstraZeneca PLC is one of the world's leading pharmaceutical groups. Net sales break down by source of income as follows: - product sales (99.8%). Net sales break down by treatment area between oncology (42.6%), cardiovascular, renal and metabolic diseases (23%), respiratory and autoimmune diseases (14.7%), and other (19.7%; inflammatory diseases, neurological diseases, gastrointestinal and infectious diseases); - collaboration revenue (0.2). Net sales are distributed geographically as follows: the United Kingdom (7.4%), Europe (22.9%), the United States (40.8%), Americas (6.1%) and Africa/Asia/Australia (22.8%).
Employees
96,100
Date Price Change Volume
08/10/26 GBX 11,892.00 -2.36% 2,276,973
07/10/26 GBX 12,180.00 +1.86% 1,721,629
06/10/26 GBX 11,958.00 +1.65% 2,189,051
05/10/26 GBX 11,764.00 -0.89% 1,619,067
02/10/26 GBX 11,870.00 -1.35% 1,659,276
Trader
Investor
Global
Quality
ESG MSCI
A
Ratings Surperformance© - AstraZeneca PLC
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
25
Last Close Price
157.15USD
Average target price
209.51USD
Spread / Average Target
+33.32%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - AstraZeneca PLC